NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: C000000047

Registered date:07/08/2005

A phase I/II study of percutaneous radiofrequency ablation for metastatic bone tumor (JIVROSG-0208)

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedSymptomatic metastatic bone tumor
Date of first enrollment2004/03/01
Target sample size33
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Radiofrequency ablation needle is percutaneouly inserted into the metastatic bone tumor and radiofrequency ablation is performed.

Outcome(s)

Primary OutcomeAdverse events
Secondary OutcomeImrovement of symptom measured by Visual Analogue Scale at 1 week after the procedure.

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1) Cardiac pacemaker. 2) Artery or nerve along the puncture route. 3) Pregnancy. 4) No symptom or VAS of less than 3.

Related Information

Contact

public contact
Name Yasuaki Arai
Address 5-1-1,Tsukiji,Chuo-ku,Tokyo,104-0045,Japan Japan
Telephone 03-3542-2511
E-mail jivrosgoffice@ml.res.ncc.go.jp
Affiliation JIVROSG, Coordinating Office Division of Diagnostic Radiology, National Cancer Center Hospital
scientific contact
Name Noboru Tanigawa
Address 10-15, Fumizono-cho, Moriguchi-shi, Osaka 570-8507, Japan Japan
Telephone 06-6992-1001
E-mail
Affiliation Kansai Medical University Department of Radiology